2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. PASK/STK37

PASK/STK37

PAS domain containing serine/threonine kinase

PASK/STK37 (also known as STK37 or PAS kinase) is a nutrient- and energy-sensing serine/threonine kinase belonging to the PAS-domain kinase family. Substrates phosphorylated by PASK/STK37 include PDX1, Wdr5, eEF1A1, and glycogen synthase; through these interactions, it regulates insulin transcription, protein translation, and glycogen and lipid synthesis. PASK/STK37 influences glucose-stimulated insulin secretion in β-cells, lipid metabolism in hepatocytes, fatty acid oxidation in skeletal muscle, as well as metabolic reprogramming and the maintenance of stemness in tumor cells. Within metabolic pathways, PASK/STK37 engages in cross-regulation with AMPK, mTOR/S6K, and nutrient signaling pathways; additionally, it can impact gene transcription through Wdr5-mediated epigenetic regulation. Given its pivotal role in glucose and lipid metabolism, β-cell function, tumor metabolism, and stem cell fate determination, PASK/STK37 has emerged as a critical research target in the fields of metabolic diseases, cancer therapeutics, and regenerative medicine.

PASK/STK37 Related Products (2):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-129571
    BioE-1115
    		Inhibitor 98.17%
    BioE-1115 is a highly selective and potent PAS kinase (PASK) inhibitor with an IC50 of ~4 nM. BioE-1115 is also a potent casein kinase 2α inhibitor with an IC50 of ~10 μM.
    BioE-1115
  • HY-114178
    CDK8-IN-2
    CDK8-IN-2 is an orally active CDK8 inhibitor of an IC50 values of 0.010 μM. CDK8-IN-2 shows a CDK19 IC50 value of 0.026 μM. CDK8-IN-2 inhibits phospho-STAT1, a pharmacodynamic biomarker of CDK8. CDK8-IN-2 inhibits WNT pathway activity. CDK8-IN-2 can be used for the research of colorectal carcinoma.
    CDK8-IN-2